These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Discovery of a potent and brain penetrant mGluR5 positive allosteric modulator. Ritzén A; Sindet R; Hentzer M; Svendsen N; Brodbeck RM; Bundgaard C Bioorg Med Chem Lett; 2009 Jun; 19(12):3275-8. PubMed ID: 19443216 [TBL] [Abstract][Full Text] [Related]
27. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI J Med Chem; 2005 Mar; 48(6):1857-72. PubMed ID: 15771431 [TBL] [Abstract][Full Text] [Related]
28. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145 [TBL] [Abstract][Full Text] [Related]
29. 2-phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor. Pelletier JC; Chengalvala M; Cottom J; Feingold I; Garrick L; Green D; Hauze D; Huselton C; Jetter J; Kao W; Kopf GS; Lundquist JT; Mann C; Mehlmann J; Rogers J; Shanno L; Wrobel J Bioorg Med Chem; 2008 Jul; 16(13):6617-40. PubMed ID: 18511284 [TBL] [Abstract][Full Text] [Related]
30. Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template. Hauze DB; Chengalvala MV; Cottom JE; Feingold IB; Garrick L; Green DM; Huselton C; Kao W; Kees K; Lundquist JT; Mann CW; Mehlmann JF; Rogers JF; Shanno L; Wrobel J; Pelletier JC Bioorg Med Chem Lett; 2009 Apr; 19(7):1986-90. PubMed ID: 19251413 [TBL] [Abstract][Full Text] [Related]
31. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives. Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347 [TBL] [Abstract][Full Text] [Related]
32. An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. East SP; Bamford S; Dietz MG; Eickmeier C; Flegg A; Ferger B; Gemkow MJ; Heilker R; Hengerer B; Kotey A; Loke P; Schänzle G; Schubert HD; Scott J; Whittaker M; Williams M; Zawadzki P; Gerlach K Bioorg Med Chem Lett; 2010 Aug; 20(16):4901-5. PubMed ID: 20638279 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5. Burdi DF; Hunt R; Fan L; Hu T; Wang J; Guo Z; Huang Z; Wu C; Hardy L; Detheux M; Orsini MA; Quinton MS; Lew R; Spear K J Med Chem; 2010 Oct; 53(19):7107-18. PubMed ID: 20809633 [TBL] [Abstract][Full Text] [Related]
34. N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Lovell KM; Felts AS; Rodriguez AL; Venable DF; Cho HP; Morrison RD; Byers FW; Daniels JS; Niswender CM; Conn PJ; Lindsley CW; Emmitte KA Bioorg Med Chem Lett; 2013 Jul; 23(13):3713-8. PubMed ID: 23727046 [TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827 [TBL] [Abstract][Full Text] [Related]
36. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Chen Y; Goudet C; Pin JP; Conn PJ Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795 [TBL] [Abstract][Full Text] [Related]
37. SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Barda DA; Wang ZQ; Britton TC; Henry SS; Jagdmann GE; Coleman DS; Johnson MP; Andis SL; Schoepp DD Bioorg Med Chem Lett; 2004 Jun; 14(12):3099-102. PubMed ID: 15149652 [TBL] [Abstract][Full Text] [Related]
38. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity. Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488 [TBL] [Abstract][Full Text] [Related]
39. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors. Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342 [TBL] [Abstract][Full Text] [Related]
40. Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. Stewart AO; Cowart MD; Moreland RB; Latshaw SP; Matulenko MA; Bhatia PA; Wang X; Daanen JF; Nelson SL; Terranova MA; Namovic MT; Donnelly-Roberts DL; Miller LN; Nakane M; Sullivan JP; Brioni JD J Med Chem; 2004 Apr; 47(9):2348-55. PubMed ID: 15084133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]